A new biotech startup called Spot Bio has launched with $40 million to develop an mRNA-based therapy for muscular dystrophy, according to Endpoints News.
The company, which has operations in both California and China, has quietly begun testing a genetic medicine aimed at restoring dystrophin. As Endpoints News reports, dystrophin is a vital muscle protein that is broken or missing in people born with Duchenne muscular dystrophy.
Duchenne is a severe, inherited muscle-wasting disease. Because the underlying problem is a faulty or absent protein, treatments that can put a working version of that protein back into muscle cells have long been a central goal for researchers. Spot Bio is betting that mRNA — the same class of technology that powered recent vaccine breakthroughs — can be used to instruct the body to produce the missing dystrophin.
The details released so far are limited. Endpoints News describes the launch as having happened "quietly," with the company already moving into testing of its candidate. The $40 million reflects the capital the startup is bringing to that early effort.
Why it matters: if an mRNA approach can reliably restore a missing structural protein like dystrophin, it would point toward a broader new way of treating genetic diseases that have few good options today — though Spot Bio's program is still at an early, unproven stage.